ACADIA Pharmaceuticals (FRA:DR6) Accounts Payable: €10.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DR6 ACADIA Pharmaceuticals Inc FRA:DR6
76 GF Score
Price €22.02
GF Value €21.73
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Accounts Payable?

ACADIA Pharmaceuticals FRA:DR6 -1.87% 76 Accounts Payable is €10.6 Mil as of Mar. 2026. GuruFocus rates FRA:DR6 with a GF Score™ of 76/100 and a GF Value™ of €21.73 (Fairly Valued). The stock has 9 warning signs investors should review.

ACADIA Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was €10.6 Mil.

ACADIA Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 (€18.5 Mil) to Dec. 2025 (€9.3 Mil) but then increased from Dec. 2025 (€9.3 Mil) to Mar. 2026 (€10.6 Mil).

ACADIA Pharmaceuticals's annual Accounts Payable declined from Dec. 2023 (€16.1 Mil) to Dec. 2024 (€15.5 Mil) and declined from Dec. 2024 (€15.5 Mil) to Dec. 2025 (€9.3 Mil).

ACADIA Pharmaceuticals Accounts Payable Related Terms

ACADIA Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Accounts Payable Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.09 12.03 16.09 15.46 9.31

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.74 17.42 18.53 9.31 10.59
FRA:DR6
76GF Score
ACADIA Pharmaceuticals Inc FRA:DR6
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €10.6 Mil mean?
ACADIA Pharmaceuticals (FRA:DR6) has a Accounts Payable of €10.6 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Accounts Payable too high?
ACADIA Pharmaceuticals' current Accounts Payable is €10.6 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Accounts Payable compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Accounts Payable of €10.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Accounts Payable is €10.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Fairly Valued. The stock's GF Value™ is €21.73, compared to a current price of €22.02 — trading 1.3% above its estimated fair value. The current Accounts Payable is €10.6 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current Accounts Payable is €10.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of €22.02 is trading 1.3% above its estimated GF Value™ of €21.73. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:DR6:

  • Accounts Payable: €10.6 Mil
  • GF Value™: €21.73 vs. price of €22.02 (1.3% above fair value)
  • GF Score™: 76/100 with 9 warning signs

No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USAACAD:Mexico
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for FRA:DR6

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.02
Price
€21.73
GF Value